DexTech Medical ABFRA:LQ0 +3.33%19 PB Ratio is 8.61 as of Jul. 12, 2026, which is 19% below its 10-year median of 10.58. GuruFocus rates FRA:LQ0 with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 1,231 Biotechnology companies, DexTech Medical AB ranks worse than 84.89% on this metric.
DexTech Medical AB stock PB Ratio (=9.45) is close to 3-year high of 9.45.
The historical rank and industry rank for DexTech Medical AB's PB Ratio or its related term are showing as below:
FRA:LQ0'
s PB Ratio Range Over the Past 10 Years
Min: 1.29 Med: 10.58 Max: 50.1
Current: 9.45
During the past 13 years, DexTech Medical AB's highest PB Ratio was 50.10. The lowest was 1.29. And the median was 10.58.
FRA:LQ0's PB Ratio is ranked worse than 84.89% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:LQ0: 9.45
During the past 12 months, DexTech Medical AB's average Book Value Per Share Growth Rate was -23.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -13.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 18.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -1.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of DexTech Medical AB was 51.60% per year. The lowest was -29.60% per year. And the median was -4.65% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
DexTech Medical AB PB Ratio Related Terms
DexTech Medical AB PB Ratio Historical Data
* Premium members only.
The historical data trend for DexTech Medical AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, DexTech Medical AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexTech Medical AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DexTech Medical AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where DexTech Medical AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
DexTech Medical AB (FRA:LQ0) has a PB Ratio of 8.61 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DexTech Medical AB and its competitors. This is 19% below median its historical median of 10.58. Over the past decade, DexTech Medical AB's PB Ratio has ranged from 1.29 to 50.10. According to the industry distribution chart, DexTech Medical AB ranks #1045 out of 1231 companies in the Biotechnology industry, placing it in the top 84.9%.
Is DexTech Medical AB's PB Ratio too high?
DexTech Medical AB's current PB Ratio of 8.61 is 19% below median its 10-year median of 10.58. Over the past 10 years, this metric has ranged from a low of 1.29 to a high of 50.10. The Biotechnology industry median PB Ratio is 2.93. DexTech Medical AB's value of 8.61 is 193.9% above this industry median. Based on the distribution chart, DexTech Medical AB ranks #1045 out of 1231 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DexTech Medical AB has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DexTech Medical AB ranks #1045 out of 1231 companies for PB Ratio. This places DexTech Medical AB in the lower half of its industry. The industry median PB Ratio is 2.93. DexTech Medical AB's value of 8.61 is 193.9% above this benchmark. Historically, DexTech Medical AB's own PB Ratio has ranged from 1.29 to 50.10 over the past decade. While the company's 10-year median is 10.58 vs. the industry median of 2.93, DexTech Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexTech Medical AB's current PB Ratio of 8.61 is 193.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DexTech Medical AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexTech Medical AB's current PB Ratio is 8.61, which is 19% below median its own 10-year median of 10.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (FRA:LQ0) has a current PB Ratio of 8.61. The current PB Ratio is 8.61, which is 19% below median its 10-year median of 10.58 and 193.9% above the Biotechnology industry median of 2.93. DexTech Medical AB's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For DexTech Medical AB (FRA:LQ0), the current PB Ratio is 8.61 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
19GF Score
Get the complete analysis for FRA:LQ0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LQ0 has been successfully added to your 
